INTRODUCTION
water for injection at concentrations of 60, 20 and 6 mg/ ml for high, mid, and low-dose levels, respectively.
Animals
Sprague-Dawley (Crl:CD(SD)) male and female rats were purchased from Charles River Laboratories Japan, Inc. (Shiga, Japan). They were housed in a clean air room maintained at 20-23°C and a relative humidity of 48-69% with a 12-hr light cycle. In the repeated-dose toxicity studies, approximately 14 g/day of CRF-1 commercial rodent chow (Oriental Yeast Co., Ltd., Tokyo, Japan) was provided to the animals. Animals in the fertility study were allowed free access to this diet. Tap water was provided to animals in all studies ad libitum. Prior to study start, the Laboratory Animal Care and Use Committee at Eisai Co., Ltd. (Tokyo, Japan) approved the study plans. These studies were performed in compliance with the Laboratory Animal Policy of Eisai.
Study designs
Repeated-dose toxicity studies EGME was orally administered to female rats (10 animals/group) at dose levels of 0, 30, 100, or 300 mg/kg for 2 or 4 weeks. The dose levels of EGME were selected based on the relevant literature (Dieter, 1993; Davis et al., 1997 ; information from Chemical Evaluation and Research Institute, Japan). A control group received an equivalent volume (5 ml/kg) of water for injection. The animals were observed daily for general condition, and body weights and food consumption were measured once every 2 to 4 days. Estrous cycle stages were determined every morning by vaginal smear. On the day of necropsy, by exsanguination from the abdominal aorta. The ovaries, adrenals, liver, kidneys, heart and spleen were weighed, -ure their maximum areas and dissected. The uterus, vagina, liver, kidneys, heart, spleen, thymus, adrenals, pituitary, bone marrow (femur), and gross lesions were also -ical sections were stained with hematoxylin and eosin (HE) and subjected to microscopic examination. To demonstrate proliferating cell nuclear antigen (PCNA) immuwere subjected to reaction with anti-rat PCNA antibody (clone: PC10; Dako Corporation, Glostrup, Denmark) and stained by the EnVision TM + Dual Link System-HRP method (Dako Corporation).
Female fertility study
The same EGME dose levels as in the repeated-dose toxicity studies (0, 30, 100, or 300 mg/kg) were selected. A control group received an equivalent volume (5 ml/ kg) of water for injection. After oral administration for 2 weeks, females (10 animals/group) were cohabited with -mation of copulation was considered Day 0 of pregnancy. The daily administration of EGME or vehicle was continued through the mating period and until Day 6 of pregnancy. Animals that did not copulate were treated until the last day of the mating period. Copulated females were necropsied on Day 14 of pregnancy, while females that did not copulate were necropsied at the end of the mating period, and thoracic and intraperitoneal organs were examined macroscopically. The numbers of corpora lutea of pregnancy, implantations and live and dead embryos were counted, and conception and pregnancy rates were calculated. In addition, vaginal smears of all females were collected during the pre-mating period to evaluate estrous stages.
Statistical analyses
Statistical analyses were performed for comparisons between treated and control groups. Differences were as body weights, food consumption in the fertility study at each time point of measurement, and absolute organ weights, as well as numbers of corpora lutea, implantations, live embryos and dead embryos were examined by --ametric Dunnett rank test was used to compare each dose group with the control. Proportional data from each litter such as pre-and post-implantation losses were examdose group with the control. Categorical data such as copulation rate, pregnancy rate and rate of occurrence of dams with resorption of all embryos were examined with the control.
RESULTS

Repeated-dose toxicity studies
There were no deaths or treatment-related clinical signs at any dose level. Although body weight gain during treatment period exhibited statistically significant increase in the 2-week study, such increases were considered within the normal range of interindividual variability. Slight decreases in food consumption were occasionally seen from Day 21 to the day of necropsy at 300 mg/kg in the 4-week study.
and resulted in cases of prolonged estrous interval and decreased frequency of estrous (Table 1) . During the second 2-week period of administration, similar estrous cycle cycling of estrous stage resumed by the end of the period of administration in most animals, continuous estrus was sporadically seen (data not shown).
Mean adrenal weight was significantly decreased at 300 mg/kg at necropsy after administration for 2 weeks weeks (Tables 3 and 4 ). There were no notable changes in weight of the ovaries, liver, kidneys, heart or spleen at necropsy after administration for 2 or 4 weeks.
Histopathological changes were observed in the ovary, vagina and uterus of animals administered for 2 or 4 weeks (Tables 5 and 6 ). The principal ovarian change induced by EGME, hypertrophy of corpora lutea, was characterized by round to polygonal luteal cells and abunmg/kg. In the affected corpora lutea, cellular debris, indi-100 mg/kg, newly formed corpora lutea were scarce after the last estrus. Although there were no newly formed corpora lutea at 300 mg/kg after administration for 2 weeks, new basophilic corpora lutea were occasionally formed during the second 2 weeks of administration in animals at the same dose. In association with the luteal change, Mean estrous cycle (days) 4.6 4.7 6.0 (n = 5) 7.8** (n = 6) Number of irregular estrous cycles 1) 2 /10 1 /10 7 /10 10 /10 1) Irregular estrous cycle means interval between estrous cycles was longer than 5 days or estrus was recorded on more than 3 consecutive days. Mean estrous cycle (days) 4.5 4.7 6.5** 9.9** Number of irregular estrous cycles 1) 3 /10 4 /10 8 /10 10 /10 1) Irregular estrous cycle means interval between estrous cycles was longer than 5 days or estrus was recorded on more than 3 consecutive days.
increased PCNA-negative large atretic follicles characterized by pyknosis and thinning of epithelial cell layer estrous changes during EGME treatment correlated well with the histopathological changes observed in the ovary. No histopathological changes were observed in small follicles including primordial and primary follicles, medium -cation characterized by the appearance of a tall columnar vacuolated epithelial cell layer and endometrial hyperplasia in the uterus were observed at 100 and/or 300 mg/kg and were considered secondary to the ovarian changes. Thymic lymphoid depletion, bone marrow hypocellular-100 mg/kg in animals treated for 2 or 4 weeks.
Female fertility study
There were no deaths or treatment-related clinical signs at any dose level. At 300 mg/kg, body weights lower than the control were noted at the end of the pre-mating period, and were more evident during the mating and gestational periods. Decreased food consumption was also observed from the pre-mating period, and continued throughout the period of treatment at 300 mg/kg. At all dose levels of EGME, continuous diestrus was frequently observed. In association with the continuous diestrus, cases of prolonged estrous cycle, irregular estrous cycle 30 mg/kg, though these estrous cycle changes were minimal at 30 mg/kg. At 300 mg/kg, durations prior to mating were prolonged, and no animals were pregnant although 7 of 10 animals copulated. Examinations at cesarean section revealed decreased numbers of corpora lutea of pregnancy, implantations, and live embryos, and increased incidence of post-implantation loss at 100 mg/kg ( Table  7) . As a result, estrous cycle alteration was the parameter most sensitive in detecting ovarian toxicity of EGME in the fertility study.
DISCUSSION
This study was conducted to determine the optimal period of administration for evaluation of ovarian morphological changes in a repeated-dose toxicity study, and a model compound, EGME, was used as part of the collaborative project. Repeated-dose toxicity and fertility studies were included in our evaluations. Disturbance of estrous cycle 100 mg/kg in repeated-dose toxicity for up to 4 weeks. It appeared that this difference in doses yielding effects was due to the ages of rats used and their feeding conditions. Administration was begun at the ages of 8 and 10 weeks in the repeated-dose toxicity and fertility studies, respectively; and in addition, food was restricted and provided ad libitum in the repeated-dose toxicity and fertility studies, respectively. Terry et al. (2005) reported that reproductive parameters such as those associated with alteration of estrous cycle and decreased numbers of corpora lutea were affected by restricted feeding. In addition, the alteration of the estrous cycle found at 30 mg/kg in the fertility were observed. There were thus no substantive differences between the fertility and repeated-dose toxicity studies in sensitivity of detection of EGME-induced ovarian toxicity.
The same ovarian changes, i.e. primary luteal lesions associated with follicular changes, were observed regardless of duration of administration in the 2-and 4-week repeated-dose toxicity studies. These findings suggestto detect the ovarian toxicity of EGME in rats. However, HE staining (A and B) and immunostaining for PCNA (C and D) in ovaries treated with vehicle or 300 mg/kg EGME for 2 weeks. A variety of luteal morphologies are observed in vehicle-treated animals (A). EGME-treated ovary contains well-organized and greatly hypertrophied corpora lutea (arrowheads) (B). Immunostaining for PCNA reveals large atretic follicles (arrowheads) which are negative for PCNA, and increased in number by EGME treatment (D) compared to vehicle treatment (C some animals exhibited adaptive signs such as the appearance of newly-formed corpora lutea and amelioration of vaginal lesions after 4-week administration. Irregularity of estrous cycles also tended to be improved after administration for 3 weeks at 300 mg/kg. However, the chronic ovarian toxicity of EGME remains unclear, since there is a report that ovarian atrophy was observed when rats were administered EGME in drinking water for 13 weeks (Dieter, 1993) . EGME-induced ovarian morphological changes in the repeated-dose toxicity studies have been reported previously, and indicated that EGME and its active metabolite, MAA, directly induce hypersecretion of progesterone in the ovarian luteal cells both in vivo and in vitro (Davis et al., 1997; Almekinder et al -ing of enlarged corpora lutea with small amounts of cellular debris, indicating apoptosis, in our repeated-dose studies also suggests primarily luteotrophic effects of EGME. The prolactin surge is known to induce luteal apoptosis in rodents (Kuranaga et al., 1999) , while EGME treatment secondarily suppressed prolactin secretion due to sustained high levels of progesterone (Davis et al., 1997) . It thus appeared that the luteal hypertrophy observed in animals in our studies treated with EGME was due to direct luteal stimulation and secondary decrease in luteal apoptosis. The increase in number of large atretic follicles was probably associated with ovulatory disorders resulting from sustained high levels of progesterone. The vaginal to be secondarily induced by hypersecretion of progesterone from luteal cells. Similar changes were induced by high levels of progesterone in the blood (Nagaoka et al., 2002; Yuan, 1991) .
In conclusion, EGME stimulated luteal cells and induced ovulation disorder, and the ovarian histopathoconsistent with the results of the female fertility study. Thus, alteration of morphology is one of the most important endpoints for detecting toxicity of EGME in the ovary, and performance of a 2-week repeated-dose toxicity toxicity of EGME.
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